<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1052243361488264&amp;ev=PageView&amp;noscript=1">

A Video From FlowMetric's CEO & Founder


FlowMetric Fast Facts

  • GLP and GCP-compliant, CLIA-certified, High Complexity Laboratory
  • Global Presence in North America, Europe, and soon Asia-Pac (late 2020)
  • Expertise in Cellular and Gene Therapy, Immunology, Oncology, and Infectious Diseases
  • Respected Global Leader in Flow Cytometry with an Ability for up to 40 Parameter Analysis
  • Quality-driven Services that Accelerate Clinical Trials, Pre-Clinical, Toxicity, and Discovery Initiatives
  • Over a Decade of Partnering with Top Pharma and Biotech Companies with >90% Repeat Business   

Why Choose FlowMetric

FlowMetric was established to deliver decision-enabling data on programs that matter the most to you. Partners choose us because of our expertise, our focus, our approach and results we have delivered.

Learn More

Tissue Dissociation Steps Video


Get Our Latest Whitepaper

New call-to-action

FlowMetric in the News

  • Press Release - FlowMetric Life Sciences, Inc. Receives CLIA High Complexity Laboratory Certification View Post Summary
  • Press Release - FlowMetric Diagnostics, Inc. Announces the Expansion of Their Core Services to Include Serological Antibody Testing for SARS-CoV-2 Exposure View Post Summary
  • The Intelligencer - Doylestown Biotechnology center, Blumberg Institute, on the front lines of coronavirus fight View Post Summary
  • Press Release - Capital Health Launches COVID-19 Antibody Testing Initiative View Post Summary

News from FlowMetric

  • CLIA & GCLP standards for clinical trial support View Post Summary

    Providing laboratory support testing for a clinical trial by meeting trial sponsors’ growing needs, all while meeting stringent regulatory requirements? It’s possible.

    Read the full article »
  • Role of Cytokine Release Syndrome (CRS) in Severe COVID-19 and Cellular Therapy View Post Summary

    What is Cytokine Release Syndrome (CRS)?

    Cytokine-associated toxicity, also known as cytokine release syndrome (CRS), is a non–antigen-specific toxicity that occurs as a result of high-level immune activation and can be triggered by a variety of factors such as certain drugs and infections.  As the name implies, several cytokines are released and elevated during CRS. The main cytokines implicated during the pathogenesis of CRS include interleukin-6 (IL-6), tumor necrosis factor (TNF-α),  interferon-γ (IFN-γ) and interleukin-10 (IL-10) (Fig.1). 

    Read the full article »
  • Global SARS-CoV-2 (Covid-19) Immunity: How Do We Get There? View Post Summary

    After more than two long months of social distancing, wearing masks, and working from home, we are all looking forward to life returning to its normal state. But one of the biggest hurdles to overcome for returning to normal social and economic activities in achieving so-called ‘herd immunity for COVID-19’ 

    Read the full article »
  • Pediatric Multi-System Inflammatory Syndrome Partially Associated with COVID-19 View Post Summary

    During the initial outbreak of the SARS-CoV-2 Global pandemic, children, in general, appeared to be relatively resilient against the virus, with only 2% of reported cases in patients under 20 years old; and world-wide, epidemiologists identified older populations with underlying conditions as being at most risk (Ludvigsson, J. F. 2020). 

    Read the full article »
  • Serological Testing for SARS-CoV-2 View Post Summary

    The challenges, the pitfalls and how we make use of it all?

    In the long-term fight against the spread of SARS-CoV-2, a second round of testing tools has been pushed to the front of the media coverage- so called ‘Serological Testing’. There has been confusion as to what these tests are, and what long-term value they can provide to this now Global pandemic. So how do we disseminate this information and determine what makes a valid serological test for SARS-CoV-2, and exactly what do we do with this information?

    Read the full article »